Must the clinical use of modern hydroxyethyl starch solutions be reevaluated now? Statement from the chairman of the German Society for Anesthesiology and Intensive Care Medicine on February 21, 2011;Muss der klinische einsatz moderner hydroxyethylstärke-lösungen gegenwärtig neu bewertet werden? Stellungnahme des präsidiums der DGAI vom 21.02.2011

Anasthesiologie und Intensivmedizin

Volumn 52, Issue 3, 2011, Pages 173-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH;

ANESTHESIST; CLINICAL PRACTICE; GERMANY; MEDICAL SOCIETY; SHORT SURVEY;

EID: 79953723473     PISSN: 01705334     EISSN: 14390256     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Schüttler J. Pros und Cons zur Infusionstherapie bei kritisch kranken Patienten in der Intensivmedizin. Anästh Intensivmed 2010;51:200-1.
2. Ogilvie MP, Pereira BMT, MG McKenney, PJ McMahon, RJ Manning, N Namias, AS Livingstone, CI Schulman, KG Proctor. J Am Coll Surg 2010; 210:870-882
3. The Crystalloid versus Hydroxyethyl Starch Trial (CHEST) Management Committee. The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Med; published online (DOI 10.1007/s00134-010-2117-9).
4. Perner A, Haase N, Wetterslev J, Aneman A, Tenhunen J, Guttormsen AB, et al. Critical Care Trials Group S. Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S - Scandinavian Starch for Severe Sepsis/Septic Shock trial): Study protocol, design and rationale for a double-blinded, randomised clinical trial. Trials 2011;12:24.
5. Shafer SL. Notice of retraction. Anesth Analg 2010;111:1567.
6. Deutsche Apothekerzeitung (DAZ) 2011;576:60-65.